The downgrade by UBS from Buy to Neutral suggests a less optimistic outlook on Exelon's stock, which could lead to reduced investor confidence and a potential decrease in stock price. The significant reduction in price target from $47 to $37 further emphasizes a bearish view on the stock's value, likely influencing short-term trading sentiment negatively.